First Light Asset Management LLC Sells 411,082 Shares of TransMedics Group, Inc. (NASDAQ:TMDX)

First Light Asset Management LLC lowered its stake in TransMedics Group, Inc. (NASDAQ:TMDX) by 57.8% during the second quarter, according to its most recent 13F filing with the SEC. The firm owned 300,600 shares of the company’s stock after selling 411,082 shares during the quarter. TransMedics Group accounts for about 4.0% of First Light Asset Management LLC’s portfolio, making the stock its 6th biggest holding. First Light Asset Management LLC owned 0.91% of TransMedics Group worth $45,276,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Farallon Capital Management LLC purchased a new stake in TransMedics Group during the 2nd quarter worth approximately $301,000. Xponance Inc. acquired a new position in TransMedics Group in the 2nd quarter valued at $306,000. Hood River Capital Management LLC purchased a new position in TransMedics Group in the 2nd quarter valued at $18,854,000. Canada Pension Plan Investment Board acquired a new stake in TransMedics Group during the 2nd quarter worth $16,086,000. Finally, SkyOak Wealth LLC purchased a new stake in shares of TransMedics Group during the second quarter worth $243,000. Hedge funds and other institutional investors own 99.67% of the company’s stock.

Insider Activity

In other news, insider Tamer I. Khayal sold 2,958 shares of TransMedics Group stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $156.77, for a total value of $463,725.66. Following the completion of the transaction, the insider now owns 20,843 shares in the company, valued at approximately $3,267,557.11. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other TransMedics Group news, insider Tamer I. Khayal sold 2,958 shares of the business’s stock in a transaction that occurred on Thursday, August 1st. The shares were sold at an average price of $156.77, for a total transaction of $463,725.66. Following the completion of the transaction, the insider now owns 20,843 shares in the company, valued at approximately $3,267,557.11. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Anil P. Ranganath sold 4,289 shares of the firm’s stock in a transaction on Wednesday, August 7th. The shares were sold at an average price of $152.20, for a total transaction of $652,785.80. Following the completion of the sale, the insider now owns 8,893 shares in the company, valued at $1,353,514.60. The disclosure for this sale can be found here. Over the last three months, insiders have sold 61,247 shares of company stock worth $9,650,880. Corporate insiders own 7.00% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the stock. Stephens raised their price target on shares of TransMedics Group from $151.00 to $178.00 and gave the stock an “overweight” rating in a research note on Friday, August 2nd. Oppenheimer boosted their target price on TransMedics Group from $125.00 to $200.00 and gave the stock an “outperform” rating in a report on Thursday, August 1st. TD Cowen increased their price target on TransMedics Group from $130.00 to $175.00 and gave the company a “buy” rating in a report on Friday, June 7th. Piper Sandler boosted their price objective on TransMedics Group from $170.00 to $180.00 and gave the stock an “overweight” rating in a research note on Thursday, August 1st. Finally, Cantor Fitzgerald assumed coverage on shares of TransMedics Group in a report on Thursday, June 6th. They issued an “overweight” rating and a $161.00 price objective for the company. One investment analyst has rated the stock with a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $171.44.

TransMedics Group Trading Down 3.3 %

TMDX opened at $159.50 on Tuesday. TransMedics Group, Inc. has a 52 week low of $36.42 and a 52 week high of $177.37. The company has a quick ratio of 8.48, a current ratio of 9.37 and a debt-to-equity ratio of 2.67. The business has a fifty day simple moving average of $155.95 and a 200-day simple moving average of $130.14. The firm has a market cap of $5.25 billion, a P/E ratio of -469.12 and a beta of 1.99.

TransMedics Group (NASDAQ:TMDX) last issued its quarterly earnings results on Wednesday, July 31st. The company reported $0.35 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.21 by $0.14. The company had revenue of $114.30 million for the quarter, compared to analyst estimates of $98.84 million. TransMedics Group had a net margin of 0.84% and a return on equity of 15.98%. The business’s revenue for the quarter was up 117.7% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.03) earnings per share. On average, equities analysts expect that TransMedics Group, Inc. will post 1.23 earnings per share for the current year.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.